Sinovac Biotech, Ltd. SVA
6.47
0.00
0.00%
as of 7 Jul
- Market cap
- $642.4M
- P/E
- 0.2×
Follow SVA
| Older periods | Jun '23 | Jun '24 | Jun '25 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
38.39% | 0.00% | 0.00% | 0.00% | |
| 26.39% | 0.00% | 0.00% | 0.00% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
29.88% | 0.00% | 0.00% | 0.00% | |
Average Days of Receivables |
18.22 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
47.08 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
4,708.18 | (1,995.03) | (1,092.78) | (1,307.47) | |
Capital Expenditures |
(860.83) | (860.14) | (455.24) | (196.17) | |
Piotroski F-Score |
4.00 | — | — | — | |
| Other line items | |||||
Cash ROIC |
23.68% | (5.07%) | (3.81%) | (8.52%) | |
Accounts Receivable Turnover |
10.59 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
1.48 | 0.00 | 0.00 | 0.00 | |
Inventory Turnover |
4.44 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
227.99 | 0.00 | 0.00 | 0.00 | |
Days of Inventory on Hand |
50.84 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
(0.20) | — | — | — | |
Research and Development Expense of Revenue |
6.92% | — | — | — | |
Selling, General and Administrative Expense of Revenue |
14.87% | — | — | — | |
Share Based Compensation of Revenue |
0.00% | — | — | — | |
Operating CF/Net income |
1.60 | 0.00 | 0.00 | 0.00 | |
Depreciation/Fixed assets |
0.29 | 0.33 | 0.33 | 0.35 | |
Capex/Depreciation |
(2.82) | (2.81) | (1.63) | (0.80) | |
Revenue per Share |
100.26 | — | — | — | |
Operating CF per Share |
55.69 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
(8.61) | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.09 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
34.69% | — | — | — |
Columns are period end dates